1. FDA grants Bristol-Myers priority review for ide-cel — Is Illumina making an $8B blunder? — Medicare may not cover the cost of the coronavirus vaccine — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Please take our quick survey on how COVID-19 is impacting your job It will only take a minute or two to respond. The survey is confidential, and does not require registration. Thank you in advance for your participation. We will provide regular updates on results as responses accumulate.
    Dismiss Notice

SAREPTA Therpeutics- BUYOUT setting up

Discussion in 'Industry Rumors' started by anonymous, Mar 23, 2016 at 11:20 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    SAREPTA Therpeutics- BUYOUT $40-$50/share ahead of FDA approval
     

  2. anonymous

    anonymous Guest

    Given the industry and market demand even that would be significantly low. Hope they don't and let them reach their ways on own, could see $50-70 by end of year easily
     
  3. anonymous

    anonymous Guest

    Bout time
     
  4. anonymous

    anonymous Guest

    Who
     
  5. anonymous

    anonymous Guest

    Big Pharma, dat who
     
  6. anonymous

    anonymous Guest

    Lmao
     
  7. anonymous

    anonymous Guest

    FDA approval ahead
     
  8. anonymous

    anonymous Guest

    $50 targets
     
  9. anonymous

    anonymous Guest

    First safe and efficient DMD drug. Sarepta Therapeutics
     
  10. anonymous

    anonymous Guest

    Try $80-120
     
  11. anonymous

    anonymous Guest

    What a month end it'll